Welcome to our dedicated page for ORGANON & CO news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & CO stock.
News about Organon & Co. (NYSE: OGN) centers on its activities as a global healthcare company focused on Women’s Health, General Medicines and biosimilars. Company press releases repeatedly describe a portfolio of over 70 products and a mission to deliver impactful medicines and solutions for a healthier every day, with particular emphasis on health needs that uniquely, disproportionately or differently affect women.
Visitors to this news page will find updates on Organon’s product and portfolio developments, including regulatory milestones, commercialization agreements and clinical data presentations. Recent announcements feature US Food and Drug Administration approvals of biosimilars such as BILDYOS and BILPREVDA for all indications of their reference products, and POHERDY as an interchangeable biosimilar to PERJETA for HER2-positive breast cancer. Organon also reports European Commission approvals for BILDYOS and BILPREVDA, expanding access to bone health treatments across the EU.
Organon’s news flow also covers women’s health and dermatology data, such as Phase 3 ADORING program results for VTAMA cream in children with atopic dermatitis, and agreements like the planned divestiture of the JADA System to Laborie and the commercialization of Nilemdo in selected European markets. Financial and corporate governance updates appear through quarterly earnings releases, capital allocation decisions, leadership changes and disclosures related to the Audit Committee investigation into Nexplanon wholesaler sales practices.
For investors, analysts and healthcare observers, the Organon news stream provides insight into how the company manages its women’s health, biosimilars and established brands portfolios, responds to regulatory developments and adjusts its leadership and balance sheet. Regularly reviewing these updates can help readers follow Organon’s evolving product mix, geographic reach and governance actions over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Organon (NYSE: OGN) is set to release its Q1 2023 financial results on May 4, 2023, before a scheduled webcast and conference call at 8:30 a.m. EDT. The live call can be accessed via the company's website, with a replay available two hours post-event. Institutional investors and analysts must register in advance to join the call.
Organon, headquartered in Jersey City, New Jersey, focuses on women's health, offering over 60 products across various therapeutic areas. The company aims to invest in innovation and strengthen its global presence, supporting growth and collaboration opportunities in the biopharmaceutical sector.
On April 19, 2023, Lifezone Metals announced the initiation of an off-take marketing process for nickel, copper, and cobalt from its Kabanga Project, believed to be among the world's largest and highest-grade nickel deposits. This move follows a Business Combination Agreement with GoGreen Investments Corporation (NYSE: GOGN). Lifezone aims to support the clean energy transition through its proprietary Hydromet Technology, which offers a low-carbon alternative to traditional smelting. The company holds marketing rights for up to 40% of the Kabanga Project's total production. RBC Capital Markets will oversee the marketing process, which is critical for monetizing the project amid rising demand from electric vehicle and battery manufacturers.
Organon (NYSE: OGN) has launched a global initiative named “Her Plan is Her Power” with a funding of